文献速递临床试验与 GCP

利伐沙班联合氯吡格雷与阿司匹林联合氯吡格雷在冠心病合并胃肠道疾病行经皮冠状动脉介入治疗患者中的疗效与安全性:非劣效随机对照试验研究方案

Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority randomized controlled trial.
PubMed 文献 · Trials · 2023-03-21

本研究为前瞻性、单中心、随机对照试验,计划纳入1020例冠心病合并胃肠道疾病行经皮冠状动脉介入治疗的患者,1:1随机接受利伐沙班10 mg联合氯吡格雷75 mg每日一次或阿司匹林100 mg联合氯吡格雷75 mg每日一次,疗程6个月。主要终点为需医疗干预的BARC 2-5型出血,次要终点为主要不良心脑血管事件复合终点。研究旨在探索兼顾抗缺血疗效与不增加胃肠道出血风险的优化抗血栓策略。

要点

  • 冠心病合并胃肠道疾病行PCI患者,利伐沙班10 mg联合氯吡格雷75 mg每日一次对比阿司匹林100 mg联合氯吡格雷75 mg每日一次,疗程6个月。
  • 主要终点为需医疗干预的BARC 2-5型出血,次要终点为包括全因死亡、心源性死亡、非致死性心肌梗死、支架血栓、缺血驱动的靶血管血运重建和卒中的MACCE复合终点。
  • 研究为前瞻性、单中心、随机对照非劣效试验,计划纳入1020例患者,1:1随机分组。

核心结论

  • 研究旨在评估利伐沙班联合氯吡格雷对比阿司匹林联合氯吡格雷在冠心病合并胃肠道疾病行PCI患者中的疗效与安全性。
  • 研究目的为探索一种优化的抗血栓策略,在达到与标准双联抗血小板治疗相同的抗缺血效果的同时不增加胃肠道出血风险。

研究设计与样本

  • 前瞻性、单中心、随机对照试验,计划纳入1020例冠心病合并胃肠道疾病行经皮冠状动脉介入治疗的患者,1:1随机分组。
  • 试验注册于中国临床试验注册中心,注册号ChiCTR2100044319;本文基于2021年9月6日版本1.4的试验方案。

关键数值与推荐

  • 干预组:利伐沙班10 mg联合氯吡格雷75 mg每日一次;对照组:阿司匹林100 mg联合氯吡格雷75 mg每日一次;两组疗程均为6个月。
  • 主要终点:需医疗干预的BARC 2-5型出血。
  • 次要终点:包括全因死亡、心源性死亡、非致死性心肌梗死、支架血栓、缺血驱动的靶血管血运重建和卒中的MACCE复合终点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is recommended for patients with coronary heart disease (CHD) undergoing percutaneous coronary intervention (PCI) to antithrombosis, meanwhile, increasing the risks of gastrointestinal bleeding. Rivaroxaban, a novel oral anticoagulant, combined with a P2Y12 receptor inhibitor reduces adverse events in patients with CHD and atrial fibrillation who underwent PCI. The effect of rivaroxaban plus P2Y12 inhibitor on reducing bleeding events in patients with CHD and gastrointestinal disease (GID) undergoing PCI remains unclear. METHOD: The study is a prospective, single-center, randomized controlled trial. A total of 1020 patients with CHD and GID undergoing PCI will be enrolled. Patients are randomized (1:1) to receive either rivaroxaban 10 mg plus clopidogrel 75 mg daily or aspirin 100 mg plus clopidogrel 75 mg daily; both treatments will last 6 months. The primary endpoint is Bleeding Academic Research Consortium (BARC) type 2-5 bleeding requiring medical intervention. The secondary endpoint is a composite of major adverse cardiovascular and cerebrovascular events (MACCE), including all-cause death, cardiac death, nonfatal myocardial infarction, stent thrombosis, ischemia-driven target vessel revascularization, and stroke. DISCUSSION: The objective of this study is to evaluate the efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with CHD and GID undergoing PCI. We aim to explore an optimized antithrombotic strategy, which achieves the same anti-ischemic effect as standard DAPT without increasing the risk of GIB, for patients with CHD and GID undergoing PCI. TRIAL REGISTRATION: This protocol is registered at the Chinese Clinical Trial Registry under the number ChiCTR2100044319. And this publication is based on version 1.4 of the trial protocol dated Sep 6, 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhou T, Gong Y, Li J, et al. Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority randomized controlled trial. Trials. 2023. PMID: 36945020. doi:10.1186/s13063-023-07236-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。